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Abstract  
As part of the ROAMER project, we aimed at revealing the share of health research budgets dedicated to 
mental health, as well as on the amounts allocated to such research for four European countries. Finland, 
France, Spain and the United Kingdom national public and non-profit funding allocated to mental health 
research in 2011 were investigated using, when possible, bottom-up approaches. Specifics of the data 
collection varied from country to country. The total amount of public and private not for profit mental 
health research funding for Finland, France, Spain and the UK was €10·2, €84·8, €16·8, and €127·6 
million, respectively. Charities accounted for a quarter of the funding in the UK and less than six per cent 
elsewhere. The share of health research dedicated to mental health ranged from 4·0% in the UK to 9·7% 
in Finland. When compared to the DALY attributable to mental disorders, Spain, France, Finland, and the 
UK invested respectively €12·5, €31·2, €39·5, and €48·7 per DALY. Among these European countries, 
there is an important gap between the level of mental health research funding and the economic and 
epidemiologic burden of mental disorders.  
Keywords - mental health research; funding; 
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Introduction 
Mental disorders are severe illnesses responsible for early mortality, as well as major disabilities, which 
have negative consequences on social, professional and family life (Hoedeman, 2012; Parks et al., 2006; 
Wahlbeck et al., 2011). In Europe the epidemiological burden is particularly high: it is estimated that each 
year 38% of the European population is affected by a mental disorder – without dementia – and in 2012 
such disorders represented 12% of the overall disease burden in terms of disability-adjusted life years 
(DALYs) (WHO, 2013b; Wittchen et al., 2011). Moreover, the situation is expected to worsen over time 
and depressive disorders are predicted to be the leading cause of morbidity in Europe by 2020 
(Directorate general for health and consumers, 2004; McCrone et al., 2008). In addition, mental disorders 
also represent a considerable economic burden, estimated at €700 million in Europe (European Union, 
Iceland, Norway and Switzerland) in 2010 by Olesen et al. (excluding dementias (F00-F09)  and general 
learning disability (F70-79)), accounting for 4% to 13% of health expenditures (when including dementias) 
in 17 Western countries in 2004, and representing 4% of the gross national product in countries of the 
European Union (Directorate general for health and consumers, 2005; Knapp et al., 2009; Olesen et al., 
2012). 
Despite the sizable burden of mental disorders in Europe, there is ample opportunity to significantly 
reduce costs and improve treatment through evidence-based interventions, disorder prevention and 
mental health promotion (Knapp et al., 2011). The development of solutions based on research has been 
identified as a priority in the mental health field by the World Health Organization and this requires 
adequate levels of funding for mental health research (WHO, 2013a). Given the substantial social and 
economic burden that mental health problems pose, it can be argued that European countries are 
investing insufficiently in this field with significant variations between countries. 
In this context, and as part of the European ROAMER project (Haro et al., 2014; Wykes et al., 2015b), our 
aim was to estimate and compare the level of public and private not-for-profit national funding for mental 
health research for the year 2011 in four European countries. 
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Experimental procedures 
General method 
Our study was carried out in four of the countries involved in the ROAMER project: Finland, France, Spain 
and the United Kingdom (UK). National public and non-profit sources of funding allocated to mental 
health research in 2011 were integrated into this study. Funding from commercial sources were not 
included as such data can be more difficult to obtain, and often cannot be apportioned between any given 
countries. Funding for mental health research was therefore defined as funding granted to institutions 
carrying out such research (core funding) and funding granted to specific projects with a mental health-
related topic in their title and/or project summary (project-based grants), either by public funders or by 
non-profit organizations. The mental health-related topics were defined according to the mental health 
field covered by the ROAMER project in other parallel studies. Therefore, all mental disorders present in 
the chapter V of the International Classification of Diseases tenth revision (ICD-10) were included in this 
study (WHO, 2010), except nicotine addiction, intellectual disability and dementia, but including topics 
related to self-harm and suicide, as it has been recommended for estimating the true burden of mental 
disorders (Vigo et al., 2016). We considered research among all age groups including children and 
adolescents. We excluded grants aimed at academic training, clinical interventions and other health 
assistance if not associated with research.  
Whenever possible, we used a bottom-up method to collect data on funding for mental health research as 
it is deemed more informative for policy making (Tarricone, 2006). We also collected the total amount of 
funding dedicated to health research, defined as all research related to any disease or medical specialty 
including biomedical and clinical research, for each considered funding body in order to determine the 
share of health research budget allocated to mental health. 
Deviations from the general method were made for each country based on its organizational and funding 
specificities. These details are presented below. 
Finland 
In Finland, we adopted a bottom-up approach to determine funding. The main public and non-profit 
funders of generic health research, national, as well as regional, were identified. Funders specifically 
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targeting only one or some medical specialities, other than mental health, were excluded. The core funding 
provided to mental health research institutions, such as university hospital departments of psychiatry, as 
well as the listing of their grants allocated to research projects focusing on mental disorders in 2011 were 
retrieved in parallel to the total amount allocated to health research. 
France 
In France, all the main public and non-profit organizations funding health research at the national level 
were selected. As the accounting systems of public research institutions do not allow for direct 
identification of core funding dedicated to mental health research, we designed an alternative top-down 
method. Core funding was estimated by multiplying the total budget of each research institution, extracted 
from the French Public Finance Act, by the ratio of the number of psychiatry-related publications to the 
total number of publications focusing on health written by researchers belonging to this institution. This 
method relies on the hypothesis that the productivity of health researchers is similar in all fields, which 
was tested in a sensitivity analysis (20% higher and lower productivity for mental health researchers in 
comparison to other health researchers). A bottom-up method was used to estimate the amount of 
project-based grants and funding by non-profit organizations, which were contacted directly to obtain this 
information. 
Spain 
In Spain, we used a bottom-up method and identified all public and non-profit funding agencies for health 
research. Public funding in Spain comes either from the State or from the regional governments of the 
seventeen autonomous communities, and both types of funding were included. We collected the list of 
grants for research infrastructures, projects, personal fellowships and awards funded by each agency in the 
areas of health and mental health during 2011. For some public funders, only the research area (but not 
the project titles) associated with personal fellowships was available. In those cases, only fellowships from 
areas of biomedicine, clinical medicine, epidemiology and psychology were included in the study for the 
computation of the total amount of health research funding. Whenever possible, the amount devoted to 
mental health research for those fellowships was estimated by extrapolating the percentage of mental 
health versus health research funding obtained for other research grants of the same agency for which the 
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title of the project was provided. For the Ministry of Education, Culture and Sports the extrapolation was 
not possible (i.e. the percentage of mental health vs. health research was not available for any grant of that 
agency), therefore we assumed that the area of psychology covered exclusively mental health research 
projects. 
United Kingdom 
In the UK, a bottom-up method was also used. Funding allocated to mental health research by the public 
sector - in particular by medical and social science research councils and programs of the National 
Institutes of Health Research (NIHR), as well as non-profit medical research awarding bodies were 
extracted through detailed scrutiny of annual reports, grant lists and websites, and personal 
communication with research funding bodies in all four countries of the UK (England, Wales, Scotland 
and Northern Ireland). In the same fashion the websites, annual reports and grant programmes of major 
research charities, such as the Wellcome Trust, as well as the UK National Lottery (through its Big Lottery 
programme) were examined. 
For the NIHR and the medical and social science research councils, only project-based funding was 
included.  
Comparison between countries 
We compared the level of mental health research funding between countries by using the total amount 
allocated to such research as well as the share of health research allocated to mental health. In addition, 
three other indicators that allowed us to take into account other countries’ characteristics were considered: 
the total amount of funding for mental health research per capita, the total funding per DALY resulting 
from mental disorders (excluding idiopathic intellectual disability and dementias) and self-harm in 2012 
(WHO, 2013b), and the percentage of the national gross domestic product (GDP) allocated to mental 
health research (The World Bank, 2011). Finally, we compared the share of health research invested in 
mental health with the burden of mental disorders over the total disease burden in terms of DALYs in 
each country in 2012 and the share of healthcare expenditures spent on mental health in all countries 
(Chevreul et al., 2013; Lafond et al., 2014; OECD, 2014; Oliva-Moreno et al., 2009). 
UK pounds were converted into euros using an average 2011 conversion rate (Eurostat, 2011). 
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Results 
Finland  
The total amount of funding allocated by public and non-profit sources to mental health research in 
Finland was €10·2 million in 2011, of which 95·3% (€9·7 million) was funded by public agencies. During 
the same period, funding for health research amounted to €104·7 million of which 9·7% was allocated to 
mental health research (see Table 1 in supplementary material). This share reached 10·7% for public 
sources and was 3·4% for non-profit sources. 
France 
In France, the total amount of funding allocated to mental health research was €84·8 million in 2011, with 
the share of health research funding devoted to mental health representing 4·1%. Public sources were the 
main contributor (94·7% of the total funding - see Table 2 in supplementary material). Based on our 
sensitivity analysis on the productivity of mental health researchers, the total amount of funding for 
mental health research in France in 2011 was between €70·5 and €99·2 million (3·4% to 4·8% of total 
health research funding). 
Spain 
In Spain, €17 million were allocated to mental health research in 2011 of which 96.8% (€16·5 million) 
were provided by public agencies. 89% of public funding emanated from the national level bodies and 
10·9% from the autonomous communities. The total share of health research expenditure allocated to 
mental health was 5·7% (5·9% for public sources and 2·3% for non-profit organizations). The State 
allocated 6·1% of its health research funding to mental health compared with 4·7% for funding from the 
autonomous communities (see Table 3 and Table 4 in supplementary material). 
United Kingdom 
In the UK, the total amount of funding dedicated to mental health research was €127·6 million of which 
76·4% was from public agencies and research councils. Charities contributed €30·1 million to mental 
health research funding of which the Wellcome Trust contributed to €10·8 million. The total share of the 
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health research spending allocated to mental health was 4·0%. This represented 6·7% of total research 
spend by public agencies and only 1·7% of charity research spend (see Table 5 in supplementary material). 
Comparison between countries 
The UK and France had very similar shares of health research budgets allocated to mental health –  
around 4% – which were 2·4 times lower than in Finland, where it was the highest, and 1·4 times lower 
than in Spain. Mental health research funding per capita ranged from €0·4 in Spain to €2·0 in the UK 
while funding per DALY ranged from €12·7 in Spain to €48·7 in the UK. Spain and France allocated the 
lowest share of their GDP to mental health research: 0·001% and 0·003%, respectively (see Table 1). The 
UK stood out in having a much greater access to funding from non-profit organisations than in the other 
three countries. In all countries, the share of health research budget allocated to mental health was 
consistently lower than the share of DALYs resulting from mental disorders and, for France, Spain and 
the UK, it was also lower than the share of healthcare expenditures spent on those disorders (see Figure 
1). 
Discussion 
In 2011, there were strong disparities in public and non-profit funding of mental health research between 
European countries: the share of health research funds dedicated to mental health in Finland was double 
that seen in France and the UK, countries with the lowest overall share of health research funds allocated 
to mental health. The differences between countries remained after adjusting for population size. In euros 
per capita, Finland and the UK invested in mental health research more than five times what Spain did 
and 1·5 times more than France. The observed differences also remained after adjusting on the size of the 
burden resulting from mental disorders: in euros spent per DALY, Spain presented the lowest figure and 
invested four times less than the UK, which presented the highest figure for this indicator. Finally, the 
differences between countries were still substantial after adjusting for GDP: in terms of share of GDP 
invested, the UK was above, investing four times more than Spain, which invested the least of its GDP in 
mental health research among all countries studied.  
Public sources were consistently the main funders of mental health research but there was an important 
difference concerning private non-for-profit funding. In the UK, where there is a strong private non-for-
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profit sector that raises money for research, as underlined by the UK Clinical Research Collaboration 
(2015), charities accounted for one quarter of the total funding invested in mental health research with a 
large contribution of the Wellcome Trust,  while in the other countries such funding represented around 
5% of the total investment. 
For all countries considered, the share of all causes' DALYs due to mental disorders was superior to the 
share of health research dedicated to mental health. It was indeed almost four times superior in France, 
where the gap was the widest, while for Finland, which had the smallest difference, it was 1·7 times higher 
than the share of health research dedicated to such disorders. 
Public and non-profit funding for mental health research seems to be particularly insufficient in Spain (in 
terms of total and per capita amounts of funding) and France (in terms of per capita amounts of funding). 
Advocacy for more investment in mental health research should be implemented in those countries. They 
could in particular benefit from the experience of the UK where non-profit organizations represents one 
of the levers to increase funding for mental health research. While mental health represents a modest 
1·7% of all charitable research funds, it is substantial as the amount of funding for all health research from 
medical research charities is well over €1 billion in the UK. The figures found in the present study have to 
be compared with a recent mapping of global mental health research funding system performed by 
RAND Europe. This found that globally one third of mental health scientific papers acknowledging 
funders were reporting studies funded by charities, foundations and non-profits organizations while two 
thirds were funded by governments. Moreover, papers acknowledging funding from such non-profits 
organizations “tend to have a higher citation impact than those acknowledging other sectors” (Pollitt et 
al., 2016). 
Even if comparison was limited by the scarcity of available studies, our results for the UK were in the 
same order of magnitude as findings from a recent report from the MQ: Transforming mental health charity, 
which estimated the investment in mental health research in the UK at €149 million per year (Kirtley, 
2015). To our knowledge, no other scientific work has estimated such investment in France, Spain and 
Finland recently. However, in a previous study with a similar methodology, we estimated the mental 
health research funding for France, the UK and the USA in 2007 (Chevreul et al., 2012). Comparison with 
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the results of this study suggests an increase both in terms of total amount of funding and share of health 
research budget allocated to mental disorders in France over time (from €20·5 million (2%) in 2007 to 
84·8 (4%) in 2011) while a slight decrease was observed in the UK (from €128·6 million (7%) in 2007 to 
€127·6 million (3·9%) in 2011). This observation in the UK was mainly due to exceptional, but 
transitional, additional funds being provided for mental health research in 2007 to compensate for a 
change in the way in which research infrastructure funds were allocated to NHS teaching hospitals. In 
addition, the share of health research funding allocated to mental health appeared to be higher in several 
developed countries outside of Europe than in three of the four European countries studied here. This 
share was indeed estimated at 16% in the USA in 2007, (Chevreul et al., 2012) 8% in Canada in 2006 
(Schachar and Ickowicz, 2014), and 10% in Australia in 2009 (Christensen et al., 2011). These three 
countries also have strong private not-for-profit sources of funding in additional to relying on the public 
sector. 
National funding for mental health research can also be complemented by funding from European 
research institutions. We previously estimated that under the 7th Framework Programme (FP7) that lasted 
from 2007 to 2013, the European Commission (EC) dedicated 5·4% of its sub-programme for health 
research (FP7 COOPERATION-HEALTH) to mental health. Finland, France, Spain and the UK received 
respectively €9·2, €16·4, €22·9 and €76·9 million of the total EC’s investment in mental health research 
(€607·1 million) during the FP7. In terms of total amount received for mental health research from the 
EC, the UK is the leading beneficiary; in euro per inhabitant obtained from the EC for mental health 
research, Finland ranks 3rd behind Iceland and the Netherlands with €203 per 100 inhabitants, while the 
UK received €124 per 100 inhabitants (Hazo et al., 2016). These results could be strongly linked to what is 
observed at the national level: as Finland and the UK have relatively high national funding of mental 
health research, this might be helping the research units to be more competitive and therefore to obtain 
international grants. On the contrary, French and Spanish mental health researchers obtained only €25 and 
€31 respectively from the EC per 100 inhabitants: their relatively low levels of national funding might 
induce a vicious circle that makes the research units less prone to respond to calls for tender and a fortiori 
to obtain grants. 
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One factor that adds to the complexity of interpreting differences in mental health funding across Europe 
is that there are substantial differences between countries of the volume and predominant form of mental 
health research conducted and funded. As part of the ROAMER project, analyses were conducted into 
geographic variation in Europe of levels of research outputs measured in English-written peer-reviewed 
publications after correcting for differences in GDP (Haro et al., 2013; Wykes et al., 2015a). ROAMER 
analyses broke down mental health research into 5 areas of research: epidemiology, randomised controlled 
trials (RCTs), genetic and imaging studies, psychotherapy and stigma-related studies. Finland produced the 
greatest amount of epidemiology research and the UK produced the greatest amount of stigma-related 
research, they ranked high in other domains as well as in public mental health (Evans-Lacko et al., 2014; 
Forsman et al., 2014). Reversely, France was ranked low in comparison to other European countries and 
Spain was slightly higher across the board in research outputs.  
The levels of total research output for France, Spain, Finland and the UK in the ROAMER analyses follow 
the respective size of the ratios of investment in mental health research to mental health DALYs in each 
country in the current study. This suggests that, out of all indicators of the level of funding in research, 
euro per DALY might be a useful metric to relate the investment in a field of health research with its 
epidemiological burden. It has already been used to determine an adequate level of research investment by 
several authors (Carter and Nguyen, 2012; Christensen et al., 2011; Nutt and Goodwin, 2011). In this 
perspective, in 2009, the Australian National Health and Medical Research Council invested €108 per 
DALY attributable to mental disorders, that is double what the UK spent per DALY attributable to 
mental disorders in 2011 (Christensen et al., 2011). Similarly, in 2012, the US National Institute for Mental 
Health invested €74·5 per DALYs (Insel, 2015; WHO, 2013b), which represented 1·5 to six times more 
than the four European countries considered in this study. 
We chose to estimate the burden of mental disorders and self-harm in terms of DALYs in this study but it 
is worth mentioning that mental disorders were also responsible for between 23 and 29% of all years lived 
with disabilities (YLD) in the four countries considered here. By contrast, such disorders were only 
responsible for 3 to 8% of all years of life lost (YLL). This might partially explain why mental health 
receives less research investment, political support still suffers from stigmatisation compared to medical 
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conditions responsible for fewer YLD but more YLL, such as cancers or cardiovascular diseases. 
However, it is known that people living with mental disorders have poorer general health compared with 
the rest of the population, their somatic diseases are also undertreated and, as a result, their life expectancy 
is far lower (Chang et al., 2011; Fleischhacker et al., 2008; Harris and Barraclough, 1998). It is certainly the 
case that years of life lost due to mental disorders are underestimated by the way in which burden of 
disease is calculated (Whiteford et al., 2013). 
Furthermore, the share of health research invested in mental health does not match the economic burden 
resulting from mental disorders; this share is already often inferior to the share of healthcare expenditures 
dedicated to mental health, which typically account for between a third and a half of the economic burden 
of mental disorders. Such disorders are associated with important direct non-medical costs (e.g. social 
services) and indirect costs (loss of productivity). Overall, they have been estimated at €461 billion in 
Europe in 2010 (Gustavsson et al., 2011), and at €37.8 billion in France, where the cost associated with 
loss of quality of life reached an additional €65.1 billion (Chevreul et al., 2013). In the UK, their economic 
and social costs per year have been estimated at €134 billion (Knapp et al., 2011). Moreover, mental 
disorders have been repeatedly found to be associated with an increase in other healthcare costs (Naylor 
Chris, 2012). 
Such relatively low investment in mental health research is particularly paradoxical given that this field of 
research benefits from a satisfying rate of return on investment in terms of health benefits and increase in 
GDP which is estimated to be at least as high as in other fields of health research (Buxton et al., 2008; 
Glover et al., 2014). The estimated time lag between mental health research investment and its benefits for 
society (9 to 14 years) may partly explain why funders – who often adopt a short-term perspective – are 
reluctant to invest in such research. Despite this, the benefits of investing in mental health research today 
are potentially considerable as both the epidemiological and economic burden associated with psychiatric 
illnesses (also associated with related physical health problems) are expected to increase dramatically over 
time (McCrone et al., 2008; Murray and Lopez, 1997). Without any additional investment in research, 
European countries will not be able to guarantee sufficient and efficient care for people with mental 
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disorders in the future. This necessary increase in funding for mental health research should be 
implemented along prioritization of key issues.  
Our results should be interpreted in the light of several limitations. First of all, we were not able to use 
exactly the same method in all countries. The specificities of the accounting system of French research 
institutions did not allow us to use a bottom-up method for the identification of core funding allocated to 
mental health research. In addition, in Spain, not all funding bodies of all autonomous communities 
provided us with their research funding data, which may lead to a slight underestimation of the overall 
funding allocated to mental health research in this country. However, as the missing data concerned only 
9·8% of Spanish funding bodies, we estimate that the impact of the missing values was minor. We might 
have also underestimated mental health research spend in the UK because it was not possible to 
disentangle mental health research from other research fields when examining core funding allocated by 
the National Institute for Health Research and the Medical Research Council, so the funding of capital 
projects and research infrastructures coming from these institutions were in general not included in the 
analysis.  
It should be mentioned as a limit that the share of health expenditures dedicated to mental health services 
and care have been found in the available literature and are from different years according to the 
countries: 2002 for Spain, 2007 for France, 2011/2012 for the UK and 2012 for Finland, which has to be 
kept in mind while comparing this indicator across countries. 
Finally, it is regrettable that we could not compare our results with figures of other areas of health 
research such as cancer or cardiovascular that could be assumed more costly that mental health research. 
Indeed, all health research fields are not equal in costs and infrastructures requirements to set up, maintain 
and deliver. For instance, epidemiological research is costly to set up, but not so costly to continue or 
maintain. It is also made less costly by having access to good quality national health registers and 
databases. Similar considerations would apply for other kinds of research that require appropriate 
infrastructure to set up and manage, for instance large-scale genetic studies, imaging studies, and large 
RCTs.  
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However, the final set of high-level priorities for mental health research identified in the ROAMER 
roadmap in most cases recommended research advances that would require setting up infrastructures 
(Wykes et al., 2015a). This includes the ROAMER recommendations of preventative and lifespan research; 
investigating causal factors in mental disorders, including –omics and biomarkers (Schumann et al., 2014); 
developing and maintaining international interdisciplinary research networks; developing and 
implementing research using scientific technological advances, including large clinical trials (Emmelkamp 
et al., 2014; van der Feltz-Cornelis et al., 2014); personalised care, and systems-level research into mental 
health services. As these priorities require substantial infrastructures to be set up, they will require 
increased national and European funding for mental health (Wykes et al., 2015b).  
Hence, despite those limitations, we were as accurate as possible in our estimations given the accounting 
systems of health research funding in the included countries. Our results underscore that mental health 
research is not funded equally across European countries at the national level and that the level of funding 
is consistently too low in comparison to both the expected rate of return on investment of such research 
and the epidemiological and economic burden incurred by mental disorders. The evidence presented here 
supports the need for urgent action across all of Europe to make the case for greater investment in mental 
health research by public and non-profit funders. 
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Abstract  
As part of the ROAMER project, we aimed at revealing the share of health research budgets dedicated to 
mental health, as well as on the amounts allocated to such research for four European countries. Finland, 
France, Spain and the United Kingdom national public and non-profit funding allocated to mental health 
research in 2011 were investigated using, when possible, bottom-up approaches. Specifics of the data 
collection varied from country to country. The total amount of public and private not for profit mental 
health research funding for Finland, France, Spain and the UK was €10·2, €84·8, €16·8, and €127·6 
million, respectively. Charities accounted for a quarter of the funding in the UK and less than six per cent 
elsewhere. The share of health research dedicated to mental health ranged from 4·0% in the UK to 9·7% 
in Finland. When compared to the DALY attributable to mental disorders, Spain, France, Finland, and the 
UK invested respectively €12·5, €31·2, €39·5, and €48·7 per DALY. Among these European countries, 
there is an important gap between the level of mental health research funding and the economic and 
epidemiologic burden of mental disorders.  
Keywords - mental health research; funding; 
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Introduction 
Mental disorders are severe illnesses responsible for early mortality, as well as major disabilities, which 
have negative consequences on social, professional and family life (Hoedeman, 2012; Parks et al., 2006; 
Wahlbeck et al., 2011). In Europe the epidemiological burden is particularly high: it is estimated that each 
year 38% of the European population is affected by a mental disorder – without dementia – and in 2012 
such disorders represented 12% of the overall disease burden in terms of disability-adjusted life years 
(DALYs) (WHO, 2013b; Wittchen et al., 2011).. Moreover, the situation is expected to worsen over time 
and depressive disorders are predicted to be the leading cause of morbidity in Europe by 2020 
(Directorate general for health and consumers, 2004; McCrone et al., 2008). In addition, mental disorders 
also represent a considerable economic burden, estimated toat €700 million in Europe (European Union, 
Iceland, Norway and Switzerland) in 2010 by Olesen et al. (excluding dementias and mental 
retardation),(F00-F09)  and general learning disability (F70-79)), accounting for 4% to 13% of health 
expenditures (when including dementias) in 17 Western countries in 2004, and representing 4% of the 
gross national product in countries of the European Union (Directorate general for health and consumers, 
2005; Knapp et al., 2009; Olesen et al., 2012). 
Despite the sizable burden of mental disorders in Europe, there is ample opportunity to significantly 
reduce costs and improve treatment through evidence-based interventions, disordersdisorder prevention 
and mental health promotion (Knapp et al., 2011). The development of solutions based on research has 
been identified as a priority in the mental health field by the World Health Organization and this requires 
adequate levels of funding for mental health research (WHO, 2013a). Given the substantial social and 
economic burden that mental health illnessesproblems pose, it can be argued that European countries are 
investing insufficiently in this field with significant variations between countries. 
In this context, and as part of the European ROAMER project (Haro et al., 2014; Wykes et al., 2015b), our 
aim was to estimate and compare the level of public and private not-for-profit national funding for mental 
health research for the year 2011 in four European countries. 
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Experimental procedures 
General method 
Our study was carried out in four of the countries involved in the ROAMER project: Finland, France, Spain 
and the United Kingdom (UK). National public and non-profit sources of funding allocated to mental 
health research in 2011 were integrated into this study. Funding from commercial sources were not 
included as such data can be more difficult to obtain, and often cannot be apportioned between any given 
countries. Funding for mental health research was therefore defined as funding granted to institutions 
carrying out such research (core funding) and funding granted to specific projects with a mental health-
related topic in their title and/or project summary (project-based grants), either by public funders or by 
non-profit organizations. The mental health-related topics were defined according to the mental health 
field covered by the ROAMER project in other parallel studies. Therefore, all mental disorders present in 
the chapter V of the International Classification of Diseases tenth revision (ICD-10) were included in this 
study (WHO, 2010), except nicotine addiction, intellectual disability and dementia, but including topics 
related to self-harm and suicide, as it has been recommended for estimating the true burden of mental 
disorders (Vigo et al., 2016). We considered research among all age groups including children and 
adolescents. We excluded grants aimed at academic training, clinical interventions and other health 
assistance if not associated with research.  
Whenever possible, we used a bottom-up method to collect data on funding for mental health research as 
it is deemed more informative for policy making (Tarricone, 2006). We also collected the total amount of 
funding dedicated to health research, defined as all research related to any disease or medical specialty 
including biomedical and clinical research, for each considered funding body in order to determine the 
share of health research budget allocated to mental health. 
Deviations from the general method were made for each country based on its organizational and funding 
specificities. These details are presented below. 
Finland 
In Finland, we adopted a bottom-up approach to determine funding. The main public and non-profit 
funders of generic health research, national, as well as regional, were identified. Funders specifically 
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targeting only one or some medical specialities, other than mental health, were excluded. The core funding 
provided to mental health research institutions, such as university hospital departments of psychiatry, as 
well as the listing of their grants allocated to research projects focusing on mental disorders in 2011 were 
retrieved in parallel to the total amount allocated to health research. 
France 
In France, all the main public and non-profit organizations funding health research at the national level 
were selected. As the accounting systems of public research institutions do not allow for direct 
identification of core funding dedicated to mental health research, we designed an alternative top-down 
method. Core funding was estimated by multiplying the total budget of each research institution, extracted 
from the French Public Finance Act, by the ratio of the number of psychiatry-related publications to the 
total number of publications focusing on health written by researchers belonging to this institution. This 
method relies on the hypothesis that the productivity of health researchers is similar in all fields, which 
was tested in a sensitivity analysis (20% higher and lower productivity for mental health researchers in 
comparison to other health researchers). A bottom-up method was used to estimate the amount of 
project-based grants and funding by non-profit organizations, which were contacted directly to obtain this 
information. 
Spain 
In Spain, we used a bottom-up method and identified all public and non-profit funding agencies for health 
research. Public funding in Spain comes either from the State or from the regional governments of the 
seventeen autonomous communities, and both types of funding were included. We collected the list of 
grants for research infrastructures, projects, personal fellowships and awards funded by each agency in the 
areas of health and mental health during 2011. For some public funders, only the research area (but not 
the project titles) associated with personal fellowships was available. In those cases, only fellowships from 
areas of biomedicine, clinical medicine, epidemiology and psychology were included in the study for the 
computation of the total amount of health research funding. Whenever possible, the amount devoted to 
mental health research for those fellowships was estimated by extrapolating the percentage of mental 
health versus health research funding obtained for other research grants of the same agency for which the 
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title of the project was provided. For the Ministry of Education, Culture and Sports the extrapolation was 
not possible (i.e. the percentage of mental health vs. health research was not available for any grant of that 
agency), therefore we assumed that the area of psychology covered exclusively mental health research 
projects. 
United Kingdom 
In the UK, a bottom-up method was also used. Funding allocated to mental health research by the public 
sector - in particular by medical and social science research councils and programs of the National 
Institutes of Health Research (NIHR), as well as non-profit medical research awarding bodies were 
extracted through detailed scrutiny of annual reports, grant lists and websites, and personal 
communication with research funding bodies in all four countries of the UK (England, Wales, Scotland 
and Northern Ireland). In the same fashion the websites, annual reports and grant programmes of major 
research charities, such as the Wellcome Trust, as well as the UK National Lottery (through its Big Lottery 
programme) were examined. 
For the NIHR and the medical and social science research councils, only project-based funding was 
included.  
Comparison between countries 
We compared the level of mental health research funding between countries by using the total amount 
allocated to such research as well as the share of health research allocated to mental health. In addition, 
three other indicators that allowed us to take into account other countries’ characteristics were considered: 
the total amount of funding for mental health research per capita, the total funding per DALY resulting 
from mental disorders (excluding idiopathic intellectual disability and dementias) and self-harm in 2012 
(WHO, 2013b), and the percentage of the national gross domestic product (GDP) allocated to mental 
health research (The World Bank, 2011). Finally, we compared the share of health research invested in 
mental health with the burden of mental disorders over the total disease burden in terms of DALYs in 
each country in 2012 and the share of healthcare expenditures spent on mental health in all countries 
(Chevreul et al., 2013; Lafond et al., 2014; OECD, 2014; Oliva-Moreno et al., 2009). 
UK pounds were converted into euros using an average 2011 conversion rate (Eurostat, 2011). 
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Results 
Finland  
The total amount of funding allocated by public and non-profit sources to mental health research in 
Finland was €10·2 million in 2011, of which 95·3% (€9·7 million) was funded by public agencies. During 
the same period, funding for health research amounted to €104·7 million of which 9·7% was allocated to 
mental health research (see Table 1 in supplementary material). This share reached 10·7% for public 
sources and was 3·4% for non-profit sources. 
France 
In France, the total amount of funding allocated to mental health research was €84·8 million in 2011, with 
the share of health research funding devoted to mental health representing 4·1%. Public sources were the 
main contributor (94·7% of the total funding) ( - see Table 2 in supplementary material). Based on our 
sensitivity analysis on the productivity of mental health researchers, the total amount of funding for 
mental health research in France in 2011 was between €70·5 and €99·2 million (3·4% to 4·8% of total 
health research funding). 
Spain 
In Spain, €17 million were allocated to mental health research in 2011 of which 96.8% (€16·5 million) 
were provided by public agencies. 89% of public funding emanated from the national level bodies and 
10·9% from the autonomous communities. The total share of health research expenditure allocated to 
mental health was 5·7% (5·9% for public sources and 2·3% for non-profit organizations). The State 
allocated 6·1% of its health research funding to mental health compared with 4·7% for funding from the 
autonomous communities (see Table 3 and Table 4 in supplementary material). 
United Kingdom 
In the UK, the total amount of funding dedicated to mental health research was €127·6 million of which 
76·4% was from public agencies and the research councils. Charities contributed €30·1 million to mental 
health research funding. of which the Wellcome Trust contributed to €10·8 million. The total share of the 
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health research spending allocated to mental health was 4·0%. This represented 6·7% of total research 
spend by public agencies and only 1·7% of charity research spend (see Table 5 in supplementary material). 
Comparison between countries 
The UK and France had very similar shares of health research budgets allocated to mental health –  
around 4% – which were 2·4 times lower than in Finland, where it was the highest, and 1·4 times lower 
than in Spain. Mental health research funding per capita ranged from €0·4 in Spain to €2·0 in the UK 
while funding per DALY ranged from €12·7 in Spain to €48·7 in the UK. Spain and France allocated the 
lowest share of their GDP to mental health research: 0·001% and 0·003%, respectively (see Table 1). The 
UK stood out in having a much greater access to funding from non-profit organisations than in the other 
three countries. In all countries, the share of health research budget allocated to mental health was 
consistently lower than the share of DALYs resulting from mental disorders and, for France, Spain and 
the UK, it was also lower than the share of healthcare expenditures spent on those disorders (see Figure 
1). 
Discussion 
In 2011, there were strong disparities in public and non-profit funding of mental health research between 
European countries: the share of health research funds dedicated to mental health in Finland was double 
that seen in France and the UK, countries with the lowest overall share of health research funds allocated 
to mental health. The differences between countries remained after adjusting for population size. In euros 
per capita, Finland and the UK invested in mental health research more than five times what Spain did 
and 1·5 times more than France. The higher level of funding in Finland and UK seems to pay off in terms 
of research publications. Two recent research mapping exercises found that Finland and UK were among 
the top European countries in the fields of public mental health and research on mental health stigma 
(Evans-Lacko et al.; Forsman et al., 2014). The observed differences also remained after adjusting on the 
size of the burden resulting from mental disorders: in euros spent per DALY, Spain presented the lowest 
figure and invested four times less than the UK, which presented the highest figure for this indicator. 
Finally, the differences between countries were still substantial after adjusting for GDP: in terms of share 
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of GDP invested, the UK was above, investing four times more than Spain, which invested the least of its 
GDP in mental health research among all countries studied.  
Public sources were consistently the main funders of mental health research but there was an important 
difference concerning the charities: inprivate non-for-profit funding. In the UK, where there is a very 
strong charitableprivate non-for-profit sector that raises money for research, as underlined by the UK 
Clinical Research Collaboration (2015), theycharities accounted for one quarter of the total funding 
invested in mental health research with a large contribution of the Wellcome Trust,  while in the other 
countries theysuch funding represented around 5% of the total investment. 
For all countries considered, the share of all causes' DALYs due to mental disorders was superior to the 
share of health research dedicated to mental health. It was indeed almost four times superior in France, 
where the gap was the widest, while for Finland, which had the smallest difference, it was 1·7 times higher 
than the share of health research dedicated to such disorders. 
Public and non-profit funding for mental health research seems to be particularly insufficient in Spain (in 
terms of total and per capita amounts of funding) and France (in terms of per capita amounts of funding). 
Advocacy for more investment in mental health research should be implemented in those countries. They 
could in particular benefit from the experience of the UK where non-profit organizations represents one 
of the levers to increase funding for mental health research. While mental health represents a modest 
1·7% of all charitable research funds, it is substantial as the amount of funding for all health research from 
medical research charities is well over €1 billion in the UK. The figures found in the present study have to 
be compared with a recent mapping of global mental health research funding system performed by 
RAND Europe. This found that globally one third of mental health scientific papers acknowledging 
funders were reporting studies funded by charities, foundations and non-profits organizations while two 
thirds were funded by governments. Moreover, papers acknowledging funding from such non-profits 
organizations “tend to have a higher citation impact than those acknowledging other sectors” (Pollitt et 
al., 2016). 
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Even if comparison was limited by the scarcity of available studies, our results for the UK were in the 
same order of magnitude as findings from a recent report from the MQ: Transforming mental health charity, 
which estimated the investment in mental health research in the UK at €149 million per year (Kirtley, 
2015). To our knowledge, no other scientific work has estimated such investment in France, Spain and 
Finland recently. However, in a previous study with a similar methodology, we estimated the mental 
health research funding for France, the UK and the USA in 2007 (Chevreul et al., 2012). Comparison with 
the results of this study suggests an increase both in terms of total amount of funding and share of health 
research budget allocated to mental disorders in France over time (from €20·5 million (2%) in 2007 to 
84·8 (4%) in 2011) while a slight decrease was observed in the UK (from €128·6 million (7%) in 2007 to 
€127·6 million (3·9%) in 2011). This observation in the UK was mainly due to exceptional, but 
transitional, additional funds being provided for mental health research in 2007 to compensate for a 
change in the way in which research infrastructure funds were allocated to NHS teaching hospitals. In 
addition, the share of health research funding allocated to mental health appeared to be higher in several 
developed countries outside of Europe than in three of the four European countries studied here. This 
share was indeed estimated at 16% in the USA in 2007,, (Chevreul et al., 2012) 8% in Canada in 2006 
(Schachar and Ickowicz, 2014), and 10% in Australia in 2009 (Christensen et al., 2011). These three 
countries also have also strong private not-for-profit sources of funding in additional to relying on the 
public sector. 
Taking into account disease burden is one of the consensual elements to determine an adequate level of 
research investment (Carter and Nguyen, 2012; Christensen et al., 2011; Nutt and Goodwin, 2011), 
overall, among the European countries considered in this study, the investment in mental health research 
remained particularly weak compared to the epidemiological burden incurred by psychiatric illnesses. In 
2009, the Australian National Health and Medical Research Council invested €108 per DALY attributable 
to mental disorders, less than what was invested in cardiovascular diseases, arthritis, cancer, asthma and 
diabetes, but still double what the UK spent per DALY attributable to mental disorders in 2011 
(Christensen et al., 2011). In 2012, the US National Institute for Mental Health invested €74·5 per DALYs 
(Insel, 2015; WHO, 2013b), which represented 1·5 to six times more than the four European countries 
considered in this study. 
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National funding for mental health research can also be complemented by funding from European 
research institutions. We previously estimated that under the 7th Framework Programme (FP7) that lasted 
from 2007 to 2013, the European Commission (EC) dedicated 5·4% of its sub-programme for health 
research (FP7 COOPERATION-HEALTH) to mental health. Finland, France, Spain and the UK received 
respectively €9·2, €16·4, €22·9 and €76·9 million of the total EC’s investment in mental health research 
(€607·1 million) during the FP7. In terms of total amount received for mental health research from the 
EC, the UK is the leading beneficiary; in euro per inhabitant obtained from the EC for mental health 
research, Finland is rankingranks 3rd behind Iceland and the Netherlands with €203 per 100 inhabitants, 
while the UK received €124 per 100 inhabitants (Hazo et al., 2016). These results could be strongly linked 
to what is observed at the national level: as Finland and the UK have relatively high national funding of 
mental health research, this might be helping the research units to be more competitive and therefore to 
obtain international grants. On the contrary, French and Spanish mental health researchers obtained 
respectively only €25 and €31 respectively from the EC per 100 inhabitants: their relatively low levels of 
national funding might induce a vicious circle that makes the research units less prone to respond to calls 
for tender and a fortiori to obtain grants. 
One factor that adds to the complexity of interpreting differences in mental health funding across Europe 
is that there are substantial differences between countries of the volume and predominant form of mental 
health research conducted and funded. As part of the ROAMER project, analyses were conducted into 
geographic variation in Europe of levels of research outputs measured in English-written peer-reviewed 
publications after correcting for differences in GDP (Haro et al., 2013; Wykes et al., 2015a). ROAMER 
analyses broke down mental health research into 5 areas of research: epidemiology, randomised controlled 
trials (RCTs), genetic and imaging studies, psychotherapy and stigma-related studies. Finland produced the 
greatest amount of epidemiology research and the UK produced the greatest amount of stigma-related 
research, they ranked high in other domains as well as in public mental health (Evans-Lacko et al., 2014; 
Forsman et al., 2014). Reversely, France was ranked low in comparison to other European countries and 
Spain was slightly higher across the board in research outputs.  
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The levels of total research output for France, Spain, Finland and the UK in the ROAMER analyses follow 
the respective size of the ratios of investment in mental health research to mental health DALYs in each 
country in the current study. This suggests that, out of all indicators of the level of funding in research, 
euro per DALY might be a useful metric to relate the investment in a field of health research with its 
epidemiological burden. It has already been used to determine an adequate level of research investment by 
several authors (Carter and Nguyen, 2012; Christensen et al., 2011; Nutt and Goodwin, 2011). In this 
perspective, in 2009, the Australian National Health and Medical Research Council invested €108 per 
DALY attributable to mental disorders, that is double what the UK spent per DALY attributable to 
mental disorders in 2011 (Christensen et al., 2011). Similarly, in 2012, the US National Institute for Mental 
Health invested €74·5 per DALYs (Insel, 2015; WHO, 2013b), which represented 1·5 to six times more 
than the four European countries considered in this study. 
Public and non-profit funding for mental health research seems to be particularly insufficient in Spain (in 
terms of total and per capita amounts of funding) and France (in terms of per capita amounts of funding). 
Advocacy for more investment in mental health research should be implemented in those countries. They 
could in particular benefit from the experience of the UK where non-profit organizations represents one 
of the levers to increase funding for mental health research. While mental health represents a modest 
1·7% of all charitable research funds, it is substantial as the amount of funding for all health research from 
medical research charities is well over €1 billion in the UK. The figures found in the present study have to 
be compared with a recent mapping of global mental health research funding system performed by the 
RAND Europe. It found that globally one third of mental health scientific papers acknowledging funders 
were reporting studies funded by charities, foundations and non-profits organizations while two thirds 
were funded by governments. Moreover papers acknowledging funding from such non-profits 
organizations “tend to have a higher citation impact than those acknowledging other sectors” (Pollitt et 
al., 2016). 
We chose to estimate the burden of mental disorders and self-harm in terms of DALYs in this study but it 
is worth mentioning that mental disorders were also responsible for between 23 and 29% of all years lived 
with disabilities (YLD) in the four countries considered here. ContrastinglyBy contrast, such disorders 
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were only responsible for 3 to 8% of all years of life lost (YLL) in those countries.). This might partially 
explain why mental health receives less research investment, political support and still suffers from 
stigmatisation compared to medical affectionsconditions responsible for lessfewer YLD but more YLL, 
such as cancers or cardiovascular diseases. However, it is known that people living with mental disorders 
have a lowerpoorer general health compared with the rest of the population, their somatic diseases are 
also undertreated and, as a result, their life expectancy can beis far lower (Chang et al., 2011; Fleischhacker 
et al., 2008; Harris and Barraclough, 1998). It is certainly the case that years of life lost due to mental 
disorders are underestimated by the way in which burden of disease is calculated (Whiteford et al., 2013).. 
Furthermore, the share of health research invested in mental health does not match the economic burden 
resulting from mental disorders; this share is already often inferior to the share of healthcare expenditures 
dedicated to mental health, which typically account for between a third and a half of the economic burden 
of mental disorders. Such illnessesdisorders are associated with important direct non-medical costs (e.g. 
social services) and indirect costs (loss of productivity). Overall, they have been estimated at €461 billion 
in Europe in 2010 (Gustavsson et al., 2011), and at €37.8 billion in France, where the cost associated with 
loss of quality of life reached an additional €65.1 billion (Chevreul et al., 2013). In the UK, their economic 
and social costs per year have been estimated at €134 billion (Knapp et al., 2011). Moreover, mental 
disorders have been repeatedly found to be associated with an increase in other healthcare costs (Naylor 
Chris, 2012). 
Such relatively low investment in mental health research is particularly paradoxical given that this field of 
research benefits from a satisfying rate of return on investment in terms of health benefits and increase in 
GDP which is estimated to be at least as high as in other fields of health research (Buxton et al., 2008; 
Glover et al., 2014). The estimated time lag between mental health research investment and its benefits for 
society (9 to 14 years) may partly explain why funders – who often adopt a short-term perspective – are 
reluctant to invest in such research. Despite this significant time lag, the benefits of investing in mental 
health research today are potentially considerable as both the epidemiological and economic burden 
associated with psychiatric illnesses (also associated with related physical health problems) are expected to 
increase dramatically over time (McCrone et al., 2008; Murray and Lopez, 1997). Without any additional 
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investment in research, European countries will not be able to guarantee sufficient and efficient care for 
people with mental disorders in the future. SuchThis necessary increase in funding for mental health 
research should be implemented along prioritization of key issues. The recommendations of the 
ROAMER project give practical guidelines on potential topics for mental health research that should be 
targeted by funding efforts in the next decade (Wykes et al., 2015).  
Our results should be interpreted in the light of several limitations. First of all, we were not able to use 
exactly the same method in all countries. The specificities of the accounting system of French research 
institutions did not allow us to use a bottom-up method for the identification of core funding allocated to 
mental health research. In addition, in Spain, not all funding bodies of all autonomous communities 
provided us with their research funding data, which may lead to a slight underestimation of the overall 
funding allocated to mental health research in this country. However, as the missing data concerned only 
9·8% of Spanish funding bodies, we estimate that the impact of the missing values was minor. We might 
have also underestimated mental health research spend in the UK because it was not possible to 
disentangle mental health research from other research fields when examining core funding allocated by 
the National Institute for Health Research and the Medical Research Council, so the funding of capital 
projects and research infrastructures coming from these institutions were in general not included in the 
analysis.  
Finally, itIt should be mentioned as a limit that the share of health expenditures dedicated to mental health 
services and care have been found in the available literature and are from different years according to the 
countries: 2002 for Spain, 2007 for France, 2011/2012 for the UK and 2012 for Finland, which has to be 
kept in mind while comparing this indicator across countries. 
DespiteFinally, it is regrettable that we could not compare our results with figures of other areas of health 
research such as cancer or cardiovascular that could be assumed more costly that mental health research. 
Indeed, all health research fields are not equal in costs and infrastructures requirements to set up, maintain 
and deliver. For instance, epidemiological research is costly to set up, but not so costly to continue or 
maintain. It is also made less costly by having access to good quality national health registers and 
databases. Similar considerations would apply for other kinds of research that require appropriate 
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infrastructure to set up and manage, for instance large-scale genetic studies, imaging studies, and large 
RCTs.  
However, the final set of high-level priorities for mental health research identified in the ROAMER 
roadmap in most cases recommended research advances that would require setting up infrastructures 
(Wykes et al., 2015a). This includes the ROAMER recommendations of preventative and lifespan research; 
investigating causal factors in mental disorders, including –omics and biomarkers (Schumann et al., 2014); 
developing and maintaining international interdisciplinary research networks; developing and 
implementing research using scientific technological advances, including large clinical trials (Emmelkamp 
et al., 2014; van der Feltz-Cornelis et al., 2014); personalised care, and systems-level research into mental 
health services. As these priorities require substantial infrastructures to be set up, they will require 
increased national and European funding for mental health (Wykes et al., 2015b).  
Hence, despite those limitations, we were as accurate as possible in our estimations given the accounting 
systems of health research funding in the included countries. Our results underscore that mental health 
research is not funded equally across European countries at the national level and that the level of funding 
is consistently too low in comparison to both the expected rate of return on investment of such research 
and the epidemiological and economic burden incurred by mental disorders. The evidence presented here 
supports the need for urgent action across all of Europe to make the case for greater investment in mental 
health research by public and non-profit funders. 
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Table 
Table 1. Comparison of mental health research funding between countries in 2011 
Indicator Finland France Spain UK 
Total public funding for mental health research (M€) 9·7 80·4 16·5 97·5 
Total charitable funding for mental health research (M€) 0·5 4·5 0·5 30·1 
Total funding for mental health research (M€) 10·2 84·8 17·0 127·6 
Health research allocated to mental health (%) 9·7 4·1 5·7 4·0 
Total funding per capita for mental health research (€ per capita) 1·9 1·3 0·4 2·0 
Total funding per DALY (€ per DALY) 39·5 31·2 12·7 48·7 
GDP allocated to mental health research (%) 0·0037 0·0030 0·0011 0·0049 
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Figure 
Figure 1 Comparison of the share of health research funding allocated to mental health, the share of healthcare 
expenditures in mental health, and the share of DALYs attributable to mental disorders by country 
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